P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P1, N=128, Active, not recruiting, Xencor, Inc. | Recruiting --> Active, not recruiting

P1, N=144, Recruiting, Vir Biotechnology, Inc. | Trial completion date: Mar 2024 --> Apr 2027 | Trial primary completion date: Sep 2023 --> Sep 2026

In patients with incurable HPV16+ solid tumors treated with SQZ-PBMC-HPV, an increase in CD8+ T cell density within the tumor parenchyma was associated with superior disease control rate and overall survival. The product composition for patients with increased CD8+ T cell density was enriched for T cells.

P1/2, N=35, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=124, Recruiting, Vir Biotechnology, Inc. | Trial completion date: Oct 2026 --> Aug 2029 | Trial primary completion date: Oct 2026 --> Aug 2029

P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2024 --> Aug 2025

P1/2, N=6, Terminated, Eureka Therapeutics Inc. | N=12 --> 6 | Trial completion date: Jun 2026 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Jun 2023; Directing efforts to the pediatric study (ARYA-2) for this product

P2/3 | N=700 | NCT05141721 | Sponsor: Gritstone bio, Inc. | "Gritstone bio...announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE...in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC)....Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases....GRANITE was generally well-tolerated with manageable adverse events; no patients have discontinued GRANITE due to adverse events....Mature PFS data expected in the third quarter of 2024; overall survival data expected in 1H 2025."

In vitro experiments showed that melanoma EV stimulates dendritic cells (DCs) maturation, and mature dendritic cells induce T lymphocyte activation. Thus, tumor cell-derived EVs can generate anti-tumor immunity in a prophylactic setting and may be potential candidates for cell-free tumor vaccines.

P2, N=15, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting

P1, N=24, Active, not recruiting, Gregory K. Friedman, MD | Recruiting --> Active, not recruiting | N=15 --> 24

P1/2, N=60, Recruiting, Enterome | Trial primary completion date: Sep 2024 --> Jun 2025

P1, N=18, Recruiting, Dwight Owen | Trial primary completion date: Dec 2023 --> Dec 2024

P1/2, N=645, Recruiting, Amunix, a Sanofi Company | Trial completion date: Dec 2026 --> Aug 2027

P2, N=110, Active, not recruiting, Imcyse SA | Phase classification: P2a --> P2

P1/2, N=131, Recruiting, NextCure, Inc. | Phase classification: P1b/2 --> P1/2

P1/2, N=134, Terminated, Atara Biotherapeutics | Trial completion date: Sep 2027 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2023 --> Nov 2023; Study was terminated as primary endpoint was not achieved

P1/2, N=150, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting

P1 | N=62 | NCT03152318 | "BostonGene...today announced the online publication...in Nature...Utilization of immunotherapy for GBM has been challenging due to the scarcity of infiltrating antitumor lymphocytes caused by a highly immunosuppressive or 'lymphocyte-depleted' tumor microenvironment (TME)....The results demonstrated a single injection of CAN-3110 activated an antitumor immune response in GBM, inducing defined changes in T cell repertoires and tumor transcriptomic signatures. These findings are evidence that intralesional onolytic viruses can convert the immunosuppressive GBM TME to an immunoactivated state that is more responsive to immunotherapy."

P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025

P1, N=60, Recruiting, BioEclipse Therapeutics | N=24 --> 60 | Trial completion date: Mar 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Aug 2025

P1/2, N=12, Recruiting, Eureka Therapeutics Inc. | Phase classification: P2 --> P1/2 | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Apr 2024

M3-like patients exhibited distinct genomic features, low immune activity and better clinical survival. The initiative identification of patients similar to M3 subtype may help to identify more patients that would benefit from ATO/ATRA treatment and deepen our understanding of the molecular mechanism of AML pathogenesis.

P1/2, N=40, Completed, Agalimmune Ltd. | Active, not recruiting --> Completed

P1/2, N=575, Recruiting, Amunix, a Sanofi Company | Phase classification: P1 --> P1/2

P2, N=15, Not yet recruiting, University Health Network, Toronto

P1, N=13, Completed, Gregory K. Friedman, MD | Active, not recruiting --> Completed

However, combined targeting of LAIR-1 and PD-L1 results in increased tumour control. Thus, additional targeting of the LAIR-1:collagen pathway with NC410 is a promising approach to treating tumours where conventional immunotherapy is ineffective.

P1, N=17, Completed, The Cooper Health System | Recruiting --> Completed | Trial completion date: Dec 2025 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023

The gene transcription profile and metabolites of FLT3-ITD mutant cells changes significantly after treatment, which might be related to the anti-FLT3-ITD AML effect. The screened DEGs, differential metabolites pathway are helpful in studying the mechanism of anti-leukemia effects and drug targets.

RNA sequencing of control cells and cells treated for 8 and 24 h revealed that there were few shared differentially expressed (DE) genes between cells treated with PVSRIPO and G207: GCLM, LANCL2, and RBM3 were enriched whilst ADAMTS1 and VEGFA were depleted. Likewise, there were few shared DE genes enriched between medulloblastoma and high-grade glioma cell lines treated with G207: GPSM2, CHECK2, SEPTIN2, EIF4G2, GCLM, GDAP1, LANCL2, and PWP1.  Treatment with G207 and PVSRIPO appear to cause disparate gene enrichment and depletion suggesting disparate molecular mechanisms in malignant pediatric brain tumors.

P1, N=43, Recruiting, Baylor College of Medicine

P2, N=40, Active, not recruiting, Pediatric Brain Tumor Consortium | Not yet recruiting --> Active, not recruiting

P1/2, N=240, Recruiting, Sanofi | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Apr 2027 --> Jan 2027

P3, N=186, Recruiting, Genelux Corporation

Notably, these pMHCs can stimulate the proliferation of stem-like memory T cells. In conclusion, this study describes a time-saving and low-cost method to isolate tumour antigen peptide MHC complexs, helping tumor antigen-specific T cell enrichment, activation, and proliferation.

P1/2, N=100, Active, not recruiting, Enterome | Phase classification: P1b/2a --> P1/2

P1/2, N=70, Active, not recruiting, Enterome | Recruiting --> Active, not recruiting | N=120 --> 70 | Trial completion date: Dec 2024 --> Nov 2025

P3, N=158, Active, not recruiting, Children's Oncology Group | Trial completion date: Oct 2025 --> Sep 2024

Combined with a lack of observed dose-limiting toxicities and a median post-treatment survival of 14.2 months (95% CI: 9.5-15.7) in IDHwt rGBM patients with positive HSV1 serology, these data provide evidence that intralesional CAN-3110 treatment can instigate immune activation in a traditionally immunologically cold tumor and that this immune activation may influence survival time—particularly when patients have had prior exposure to HSV1. (clinicaltrials.gov NCT03152318)

C2a/1vsC2a/2vsC3: median treatment duration 1.4vs3.2vs4.8 months, disease control rate 22%vs40%vs88%, median PFS 1.6vs3.6vs5.5 months; median survival 9.0vs12.6vstoo early (C3 median FU 8.3 mo, survival ongoing up to 2 years). Further follow-up will be presented.